Leerink Swann Initiates Paratek Pharmaceuticals With Outperform

Leerink Swann initiated coverage on Paratek Pharmaceuticals Inc PRTK with a Outperform rating. The target price for Paratek Pharmaceuticals is set to $43. Paratek Pharmaceuticals shares have dropped 25.03 percent over the past 52 weeks, while the S&P 500 index has surged 12.95 percent in the same period. Paratek Pharmaceuticals' shares closed at $27.80 yesterday.